Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Detalles Bibliográficos
Autores principales: Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., van de Loosdrecht, A., Weigert, A., Metzeler, K. H., Fenaux, P., Medyouf, H., Platzbecker, U., Ades, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624604/
https://www.ncbi.nlm.nih.gov/pubmed/37735558
http://dx.doi.org/10.1038/s41375-023-02029-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624604/
https://www.ncbi.nlm.nih.gov/pubmed/37735558
http://dx.doi.org/10.1038/s41375-023-02029-1

Ejemplares similares